The First Affiliated Hospital of Xiamen University

ACTIVE

No.10, Shanggu Street, Zhenhai Road, Siming District, 广东省深圳市, 广东省, Chinawww.xmfh.com.cn

Clinical Trials

114

17 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

32.5%

Not Applicable

28.9%

Phase 1

13.2%

Phase 4

3.5%

Phase 3

1.8%

Early Phase 1

0.9%

Trial Status Distribution

Active, not recruiting

3.5%

Completed

16.7%

Enrolling By Invitation

2.6%

Not yet recruiting

8.8%

Recruiting

57.9%

Terminated

0.9%

Unknown

9.7%

Clinical Trials

Trials sponsored by this organization (114)

Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 2

Recruiting

interventional

Nov 202630 participants

Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

Not Applicable

Recruiting

interventional

Aug 202630 participants

Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer

Not Applicable

Recruiting

interventional

Aug 2026120 participants

Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

Phase 2

Recruiting

interventional

Jul 202653 participants

DLL3-Targeted PET/CT in Small Cell Lung Cancer

Not Applicable

Recruiting

interventional

May 202620 participants

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

Not Applicable

Recruiting

interventional

May 202640 participants

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Phase 1

Recruiting

interventional

Apr 202645 participants

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Phase 2

Recruiting

interventional

Apr 20268 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations